Samar Mahapatra*
The biochemical backdrop of cancer is exceedingly complex, making individualized therapeutic interventions difficult. Predictive medicine promises to remove this barrier by combining data from various ‘subsystems,' including as the host, the external environment, the tumours, and the tumours micro-environment. Immunogenetics is a crucial technique for understanding lymphoid cancer ontogeny at both a cell-intrinsic and cell-extrinsic level, i.e. by analyzing micro-environmental interactions, with the goal of developing predictive treatment. Next Generation Sequencing (NGS), which allows for a detailed analysis of immunological receptors. Indeed, NGS immunogenic analysis (immune-seq) has emerged as a critical tool for understanding cancer pathophysiology and increasing clinical decision-making accuracy in oncology. Immune-seq has uses in lymphoid malignancies, such as helping in diagnosis by distinguishing between reactive and non-reactive diseases as well as disease monitoring through reliable minimal residual disease diagnosis.